Bioactivity of methyl palmitate obtained from a mangroove plant Salvadora persica L

ABSTRACT

The invention discloses a process of extracting, fractionating and purifying bioactive molecules from an associated mangrove plant, methods of screening for pharmacological activities of crude extract, its fractions and purified compounds and use of methyl palmitate obtained from the crude extract as a muscurine antagonist.

FIELD OF INVENTION

[0001] The present invention relates to a novel muscurine antagonist obtained from an associated mangrove plant called Salvadora persica Linneaus 1753 collected from estuarine mangrove swamps of Goa, India. Particularly, the present invention relates to the use of methyl palmitate isolated from the plant Salvadora persica as a muscurine antagonist.

BACKGROUND OF THE INVENTION

[0002] Methyl palmitate is a fatty acid methyl ester. It is prepared commercially from naturally occurring edible fats and oils. These compounds are widely used indirectly in a wide range of food, pharmaceutical, cosmetic and industrial applications (Pearson, R. Report of the FAME (Fatty acid Methyl Esters) Task Force, Jan. 9, 1997). In the same report methyl esters including methyl palmitate, tested for oral toxicity in rats is given. It was proved to be nontoxic. It is also described that administration of an emulsion of methyl palmitate to mice by oral intubation or intraperitoneal injection produced no alteration in organ weight or phagocytic function of the reticuoendothelial system. Environment mutagen 8, (Suppl 7): 1-119, 1986 (quoted from Pearson, R. Report of the FAME (Fatty acid Methyl Esters) Task Force, Jan. 9, 1997) reported that methyl palmitate was devoid of any mutagenic effect based on the tests on Salmonella and/mammalian microsome assays. The methyl palmitate though showed sensitivity of rabbit's skin to the compound, the results with human skin proved to have a very mild effect. Methyl esters of fatty acids used can be used as supplementary source of fat for animal feeds.

[0003] “Muscarinic actions” are the actions produced as a result of acetylcholine released from the post-ganglionic parasympathetic nerve endings or the actions resulting from exogenously administered acetylcholine on the receptors of organs with post-ganglionic parasympathetic nerve supply. The muscarinic actions of both endogenously released as well as exogenously administered acetylcholine are blocked by atropine. The designation “muscarinic actions come from the fact that these actions are similar to those produced by the poisonous mushroom alkaloid muscarine (Satoskar, R. S. and S. D. Bhandarkar. Pharmacology and pharmacotherapeutics, vol.1. Popular Prakashan Bombay. 1990)

[0004] Acetylcholine acts on two types of receptors, namely muscarinic and nicotinic (Goodman & Gilman: In: The pharmacological basis of therapeutics. 9^(th) edition 1997. McGraw-Hill, health profession's division, New York; 1905 PP.). Since the activity of the crude extract of the Salvadora persica plant was seen on smooth muscle, only muscarinic receptors have been studied (Nazarine, F. Ph.D. Thesis, Goa University, 1998).

[0005] A large number of binding and functional studies have indicated the existence of 5 subtypes of muscarinic receptors namely, M₁, M₂, M₃, M₄ and M₅ (Birdsall, N. J. M and Hulme F. C.; 1983; Trends Pharmacological Sciences, 4: 459-461, 1983). The most important are the M₁, M₂ and M3, muscarinic receptor subtypes. M₁ receptors are found in the stomach and mediate gastric secretions whereas M₂ receptors are found in the myocardium of the heart and M₃ are found in the ileum and bladder detrusor muscles and cause smooth muscle contractions.

[0006] Thompson Wayne J, Ransom Richard W; Mallorga Pierre; Sugrue Michael F' In Patent No. WO 9716192 published on May 9,1997 the antimuscarinic activity of derivatives of piperdin and described their use in the treatment and/or prevention of myopia, commonly known as near-sightedness.

[0007] Haertel, Bernd and Klimek, Peter in patent No. DE 4136811 published on May 13, 1993 discloses a skin cleanser especially for removing paint containing methyl, ethyl and/or isopropyl palmitate with some solvents and emulsifiers. Jeanne, R. L. and Henderson, G in U.S. Pat. No. 5,109,022 published on Apr. 28, 1992 describes a composition which contains methyl palmitate and some other compounds and is useful for repelling flying, biting and stinging insects. Khwaja, Tasneem, A. and Friedman; Elliot P.; In U.S. Pat. No. 6,039,950 published on Mar. 21, 2000, described formulations of several pharmaceutical grade compounds including fatty esters from the Saw Palmetto which is a small palm found in southern United States. Ueoka, Hideaki; tabata; Osamu; Sakamoto; Tohru. In U.S. Pat. No. 6.049,013 published on Apr. 11, 2000 disclosed that in methods of producing alcohols, the fatty acids (one example is of methyl palmitate) could be extracted from Coconut, Palm and Palm kernel for this use.

[0008] Wood; Ronald W. el-Fawal; hassan, A.n.; Graefe, John F.; Chen; Lung C.; Shojaie; Jalil; In patent published on Oct. 13, 1998 (U.S. Pat. No. 5,821,249) described production of anhydroecgonine methylester (MEG) by heating cocaine base (“crack”) and their use as anticholinergic agents. MEG alone and in combination with cocaine was tested for action on isolated tracheal rings stimulated to contact with acetylcholine.

[0009] There is no patent available on the antimuscarinic activity of methyl palmitate. The present invention for the first time discloses the effect of methyl palmitate on M₁ receptors by observing gastric acidity by pyloric ligation under basal conditions. Like atropine, the compound methyl palmitate decreased free acidity. However, in the studies conducted, it was 50 times less potent than the standard antagonist atropine. M₂ muscarinic receptors found in the conducting tissue and the myocardium of the heart mediate both the bradycardia and the negative inotropic effect of cholinergic stimulation. The present invention relates to the comparative effect of methyl palmitate and atropine on the rate and force of contraction of the guinea pig atria. It describes the inhibitory effect of atropine. The invention describes that the compound methyl palmitate had no such effect in the dosage range used showing that it probably does not block M₂ receptors. Though the reason of this effect is not known, yet our invention for the first time describes the ability of the compound methyl palmitate to distinguish between the muscarinic receptors in the atrium and elsewhere in the body. The very reason that methyl palmitate does not affect the M₂ receptors of the atrium confirms the heterogeneity of muscarinic receptors.

[0010] As used herein the term “antimuscarinic activity” means the antagonistic activity on muscarinic receptors where antagonistic activity refers to the inhibitory effect of atropine and the said compound. The “heterogeneity of muscarinic receptors” means the ability of the said compound to distinguish between the muscarinic receptors in the atrium and elsewhere in the body. “The selectivity of the compound” means its inhibitory action only on M₁ and M₃ muscarinic receptors. “The competitive antagonism” means the compound produced a shift to the right in the dose response curves of the acetylcholine with the maximum response remaining the same. In gastric acidity experiments the compound was injected subcutaneously as per the body weight of the rat measured in kilograms and written as Kg. s.c. where “s.c.” means subcutaneous.

[0011] The approach adopted for antagonistic activity screening by pharmacological methods is described for the first time for this compound. The invention describes that methyl palmitate produces a shift to the right in the dose response curves of acetylcholine with the maximal response remaining the same. It further discloses that the competitive antagonism shown by the said compound is reversible in nature. methyl palmitate blocks M₃ receptors in the same way as atropine, though it is 2.2 times less potent.

OBJECTS OF THE INVENTION

[0012] The main object of the present invention is study the compound methyl palmitate purified from the extract of the plant Salvadora persica for its anti-muscarinic activity.

[0013] Another object of the present invention is to study the heterogeneity of methyl palmitate as a muscarinic receptor.

[0014] Still another object of the present invention is to study the comparative effect of methyl palmitate and atropine during in vivo and in vitro experiments.

[0015] One more object of the present invention is to detect the effect of methyl palmitate on the dose response curve of acetylchlorine.

[0016] One another object of the present invention is to detect the effect of methyl palmitate in rats.

[0017] Another object of the present invention is to find out the effect of the methyl palmitate in guinea pigs.

SUMMARY OF THE INVENTION

[0018] The present invention seeks to overcome the drawbacks inherent in the prior art by providing highly efficient and selective methods for screening antimuscarinic activity of methyl palmitate compound purified from the plant Salvadora persica and discloses the use of this compound as a muscurine antagonist.

DETAILED DESCRIPTION OF THE INVENTION

[0019] Accordingly, the present invention provides a process for obtaining methyl palmitate from a mangrove plant source namely Salvadora persica, said process comprising:

[0020] (i) obtaining an extract from Salvadora persica and

[0021] (ii) extracting and purifying the biologically active extract to obtain methyl palmitate from the extract.

[0022] Also, the present invention provides a process for preparation of the extract comprising methyl palmitate from the mangrove plant source Salvadora persica, said process comprising:

[0023] (i) air-drying the plant parts;

[0024] (ii) immersing the plant parts in 90 percent aqueous methanol for one week at room temperature (28±2° C.);

[0025] (iii) filtering the methanolic extract by conventional methods; and

[0026] (iv) evaporating the methalonic extract at room temperature (28±2° C.) to obtain a crude extract.

[0027] More particularly, the present invention provides a process for the extraction and purification of a biologically active methyl palmitate, useful as muscarine antagonist from an extract of Salvadora persica mangrove plant, said process comprising:

[0028] a) obtaining a solvent extract from the plant parts of Salvadora persica,

[0029] b) testing the extract using methods of pharmacology;

[0030] c) fractionating the extract;

[0031] d) testing the fractions using methods of pharmacology;

[0032] e) isolating the pure compound by a conventional method;

[0033] f) testing the pure compound by using methods of pharmacology; and

[0034] g) identifying the compound by conventional methods.

[0035] In an embodiment of the present invention, the plant parts of Salvadora persica are selected from leaves, stems and flowers.

[0036] In another embodiment of the present invention, the extract is obtained using solvents such as chloroform and hexane.

[0037] In yet another embodiment of the present invention, the methyl palmitate molecule is characterized by: Molecular formula: C₁₆H₃₂O₂ Molecular weight: 256 Melting point: 30° C.

[0038] ‘Extract’ as used herein denotes the extract obtained from the plant Salvadora persica.

[0039] In still another embodiment of the present invention, methyl palmitate is capable of distinguishing between muscarinic receptors of atrium and other parts of the body and shows heterogeneity of muscarinic receptors. Methyl palmitate shows competitive antagonism, which is reversible in nature.

[0040] In one another embodiment of the present invention, methyl palmitate obtained inhibits gastric acidity and gastrointestinal disorders. The applicants have found that methyl palmitate inhibits gastric acidity as it exhibits activity on the M1 receptors found in stomach of rat. It also exhibits activity against M3 receptors found in ileal and bladder detrusor muscles of pig.

[0041] It is also found that methyl palmitate does not block M2 receptors and thereby does not have inhibitory effect on the contractions of atrial muscles of guinea pig in the dosage range used.

[0042] In still another embodiment of the present invention, methyl palmitate produces a right shift of the dosage response curves of acetyl chlorine with the maximum response remaining the same.

[0043] In one more embodiment of the present invention, methyl palmitate shows muscarinic activity with a milder potency than atropine.

[0044] Based on the studies conducted, the invention provides a novel muscurine antagonist obtained from the plant Salvadora persica. The applicants have found that the extract as well as methyl palmitate obtained from the extract of Salvadora persica acts as a muscurine antagonist.

[0045] Additionally, the invention provides pharmaceutical compositions useful as muscarine antagonist, comprising an effective amount of extract obtained from the mangrove plant Salvadora persica, optionally with conventional additives. The composition may also contain methyl palmitate as active ingredient. The amount of the active ingredient in the composition may be readily determined by a person skilled in the art depending on factors such as patient being treated, his body weight etc. However, the effective amount may be in the range of 0.1 to 10 mg/kg body weight.

[0046] Further, the applicants have found that the compound methyl palmitate obtained from the plant has the general capacity to impact muscle contractions, by slowing down or halting contractions. As a result, it is capable of reducing spasms in smooth muscles, hence acting as an anti-muscuranic agent. Thus, the compound acts as an effective ‘muscurine antagonist’. Preferably, the method of treatment comprises the step of administration of a composition containing the compound methyl palmitate obtained from Salvadora persica to a subject in need thereof. The diseases for which the composition may be administered are renal colics, bronchial asthma, abdominal cramps, motion sickness and prevention of premature delivery. The Applicants believe that the compound methyl palmitate in the extract is responsible for the above activities.

[0047] In an embodiment of the present invention, the dose response curves of the standard agonistic drug acetyl chlorine were carried out in absence and presence of methyl palmitate on guinea pig atria for the said activity on M₂ and M₃ receptors.

[0048] In another embodiment of the present invention, for the purpose of comparison, three doses of atropine were used for testing antimuscarinic activity on M₃ receptors on ileal and bladder muscles, and the amount of the doses are:

[0049] 35×10⁻⁶ moles/ml of bath concentration;

[0050] 86×10⁻⁶ moles/ml of bath concentration; and

[0051] 173×10⁻⁶ moles/ml of bath concentration.

[0052] In yet another embodiment of the present invention, for comparative purposes, three doses of atropine were administered on M₂ receptors and the amount of the doses are:

[0053] 0.4×10⁻⁶ moles/ml of bath concentration;

[0054] 0.9×10⁻⁶ moles/ml of bath concentration;

[0055] 1.7×10⁻⁶ moles/ml of bath concentration;

[0056] In still another embodiment of the present invention, for comparative purposes, three doses of atropine were administered to M₁ receptor for testing gastric acidity:

[0057] 0.01 mg/kg of the body weight of rat;

[0058] 0.05 mg/kg of the body weight of rat; and

[0059] 0.10 mg/kg of the body weight of rat.

[0060] In another embodiment the percent inhibition of gastric acidity by the compound methyl palmitate was

[0061] 50.72% when the dose was 1 mg/kg of the body weight of rat;

[0062] 55% when the dose was 3 mg/kg of the body weight of rat; and

[0063] 91.5% when the dose was 5 mg/kg of the body weight of rat.

DESCRIPTION OF THE TABLES

[0064] Table 1:

[0065] Effect of methyl palmitate and atropine on gastric acidity in rats.

DETAILS OF THE FIGURES

[0066]FIG. 1: Percent inhibition in gastric acidity with methyl palmitate

[0067]FIG. 2: Percent inhibition in gastric acidity with atropine

[0068]FIG. 3: Dose response curve of acetyl choline on guinea pig atria in absence and presence of methyl palmitate

[0069]FIG. 4: Dose response curve of acetyl choline on guinea pig atria in absence and presence of atropine.

[0070]FIG. 5: Dose response curve of acetyl choline on guinea pig ileum in absence and presence of methyl palmitate.

[0071]FIG. 6: Dose response curve of acetyl choline on guinea pig ileum in absence and presence of atropine.

[0072]FIG. 7: Dose response curve of acetyl choline on guinea pig bladder in absence and presence of methyl palmitate.

[0073]FIG. 8: Dose response curve of acetyl choline on guinea pig bladder in absence and presence of atropine.

ADVANTAGES OF THE INVENTION

[0074] The invention pertains to a new muscarinic antagonist purified from a novel source of an associated mangrove plant.

[0075] This invention can be utilized for adopting the methods of pharmacological screening of bioactive molecules for antimuscarinic activity both in vivo and in vitro experiments. The comparative effect of methyl palmitate and atropine on M₁, M₂, and M₃ receptors discloses the inhibitory effect of methyl palmitate on M₁ and M₃ whereas atropine has inhibitory effect on all the three receptors.

[0076] The present invention also contemplates that the compound methyl palmitate had no such effect in the dosage range used showing that it probably does not block M₂ receptors.

[0077] This ability of the methyl palmitate in distinguishing muscarinic receptors can have a wider applied aspect in making pharmaceutical compositions for clincal testing of selective tissue remedies.

[0078] Thus in a preferred mode of use the finding that the methyl palmitate produces a shift to the right in the dose response curves of acetylcholine with the maximal response curves of acetyl choline remaining the same.

[0079] The present invention also contemplates the finding that the antagonism is competitive as shown by the said compound. Methyl palmitate blocks M₃ receptors in the same way as atropine, though it is 2.2 times less potent.

[0080] The selectivity and lower potency characteristic of a compound together can make a good combination in testing compositions to have an added advantage of overcoming side effects on unrelated tissues/organs.

[0081] In a preferred mode of use the compound methyl palmitate can be a potential inhibitor of gastric acidity and gastrointestinal disorders. The percent inhibition of gastric acidity was directly proportional to the dose of the said compound.

EXAMPLE 1 Chemicals, Reagents, Apparatus Used and Their Sources

[0082] Name of reagents/chemicals/glassware Company Acetylcholine chloride Hopkins & Williams Ltd.) Atropine SIGMA Chloroform S.d.fine chemicals Ether S.d.fine chemicals Saline Glaxo Burette Borosil

[0083] Apparatus:

[0084] 1. Physiograph.

[0085] Company: Biodevices,

[0086] Ambala, India.

[0087] 2. Force Transducer

[0088] Model No. T-305

[0089] Co.: GRASS,USA

[0090] 3. Organ Bath

[0091] Ambala,

[0092] India

[0093] The methods of screening and results of antimuscarinic activity of methyl palmitate an aliphatic ester extracted and purified from an associated mangrove plant identified as Salvadora persica are disclosed.

EXAMPLE 2

[0094] Collection of the mangrove plant Salvadora persica L from the coast of Goa was along Ribandar, near the mouth of the Mandovi estuary, upstream. This species is ubiquitous to the coastal areas of Goa and was collected manually from the intertidal banks.

EXAMPLE 3

[0095] Processing of the collected mangroves were washed first with seawater followed by tap water. The undesired materials were sifted out while washing with tap water to get rid of the salts. The leaves, stems, and flowers of the associated mangrove plant were air dried. After drying, the plant material was cut into small pieces and immersed in the solvent 90% aqueous methanol for a week for extraction. Care was taken that these were properly soaked/dipped in the solvent so as to check putrefaction.

EXAMPLE 4

[0096] Extraction and preparation of crude extract was carried out by cold percolation method at room temperature and by solvent evaporation at a water bath (temperature 50° C.) under reduced pressure. This helps in protection of any heat labile metabolite present in it. Re-extraction was done twice until the extract was concentrated under vacuum to obtain the crude extract.

EXAMPLE 5 Fractionation of the Crude Extract

[0097] The crude extract was partitioned into petroleum ether, chloroform, n-butanol and aqueous fractions using a separating funnel. Petroleum ether was added to the extract in the separating funnel and separated out. Next, chloroform was added to the residue, mixed well and the lower layer separated. To the residue butanol was added and the top layer represented the butanol fraction and lower layer the aqueous fraction. Extraction of each fraction was done thrice and whenever there was emulsion sodium chloride was added for breaking the emulsion. Sodium sulphate was added to chloroform and butanol fractions to remove traces of water before concentration. All the fractions were concentrated in the same manner as the crude extract. These fractions were tested for the same pharmacological activity as the parent crude extract.

[0098] Pharmacological Testing of Crude Extract

[0099] Female, virgin, guinea pigs weighing around 300 to 350 g, housed under uniform husbandry conditions (temperature 25±1° C.) were used. The animals were starved 24 hours prior to the experiment, only water was provided adlibitum.

[0100] The isolated guinea pig ileum was used to study the antispasmodic anticholinergic oxytocic and tocolytic activity.

[0101] All physiological solutions were prepared fresh at the time of the experiment.

EXAMPLE 6

[0102] For pharmacological testing on guinea pig ileum the guinea-pig was sacrificed by stunning with a sharp blow on its head. The abdomen was quickly cut open. Towards the lower end of the abdomen was the greenish sac-like caecum. The small intestine was marked by a localized thickening in the wall—a Peyer's patch of lymphoid tissue. The lowermost 10 cm of ileum nearest to the ileocaecal junction was discarded. From there, about 10 cm of ileal tissue was cut off and freed of mesentery and placed in a petridish containing warm Tyrode solution. The lumen of the ileum was gently rinsed out using a hypodermic syringe filled with Tyrode solution to prevent accumulation of mucus in the lumen. The ileum was cut into small segments of about 3-4 cms in length in the fully relaxed state. The lower end was sutured to a tissue holder, by making a loop first to avoid direct contact with the tube. The tissue was positioned in an organ bath of capacity 10 ml containing tyrode solution aerated with air at 37° C. The thread of the upper end of the ileum was fixed to the lever of a force transducer (FT 03) which measures muscle contractions isometrically and connected to an Grass Polygraph (Model 7). The ileal tissue was kept to stabilize in Tyrode solution for 30 minutes and the fluid in the organ bath was renewed every 10 mins.

[0103] Two to four doses of spasmogens (acetylcholine, histamine, 5 hydroxytryptamine, barium chloride and nicotine) were added to the bath to obtain uniform amplitude with a contact period of 30 seconds of contraction which was recorded on the polygraph. The aqueous solutions of the extracts and fractions were added 1 min before the addition of the spasmogens. Effect of graded doses of the extracts (50×250 micro. Grams/ml) on the spasmogen—induced contraction was seen and percent reduction of contraction measured as per the formula given below. ${\% \quad I\quad n\quad h\quad i\quad b\quad i\quad t\quad i\quad o\quad n} = {\frac{X - Y}{X} \times 100}$

[0104] Wherein

[0105] X=Height of standard contraction (mm)

[0106] Y=Height of standard contraction in presence of the extract (mm)

EXAMPLE 7

[0107] For experiments upon isolated guinea pig uterus the bicornuate uterus was dissected out and freed of fat tissue. One horn was cut-off and kept in a shallow dish containing the physiological solution—de Jalon's fluid which was previously aerated with air. Air was preferred to oxygen as the tissue was thin and saturation was faster. The two ends were sutured. The lower end of the uterine strip was tied to a tissue holder and suspended in an organ bath of 10 ml capacity and the upper end being more sensitive, to the lever of the force transducer (FT 03) connected to a Grass Polygraph (Model 7) (FIG. 6). It was left to stabilize for 30 mins., renewing the physiological solution in the bath every 10 mins. The response of the uterus to different doses of the extract (50×250 μg/ml) against standard uterine stimulants like oxytocin and PG F_(2α) (PG F sub.two.alpha) with a contact period of 60 seconds (was recorded on the polygraph). The tocolytic effect was evaluated by the formula given below. ${\% \quad I\quad n\quad h\quad i\quad b\quad i\quad t\quad i\quad o\quad n} = {\frac{X - Y}{X} \times 100}$

[0108] Wherein

[0109] X=Height of standard contraction (mm)

[0110] Y=Height of standard contraction in presence of the extract (mm)

EXAMPLE 8

[0111] Phamacological Testing of Pure Compounds

[0112] In vitro experiments: The active fractions were isolated for anticholinergic activity, the five compounds isolated were tested only on isolated guinea pig ileum. The longitudinal ileal muscle from a freshly killed guinea-pig was suspended in an organ bath of 10 ml capacity, filled with Tyrode solution and aerated with air.

[0113] Two or four doses of the standard drug acetylcholine were added to the bath to obtain uniform amplitude with a contact period of 30 seconds, the contractions of which were recorded on a polygraph. The five compounds isolated were tested in doses of 196 and 392×10⁻⁶ moles per ml of bath concentration. The effect of the compounds against acetylcholine—induced contraction was seen and the percentage reduction of contraction measured.

EXAMPLE 9 Preparation of Stock Solutions and Various Doses of Methyl Palmitate, Acetylcholine and Atropine

[0114] Methyl palmitate purified from the chloroform fraction of the crude extract of the said plant was in the powder form. To make its stock solution of 1 mg/ml strength, the weighed powder was first dissolved in a drop of chloroform and then the volume was made to one milliliter by adding distilled water. The stock solution was stored at 4 degree C. The different concentrations of the doses were prepared by diluting the stock solution with distilled water. Acetylcholine was used as the standard muscarinic drug, while atropine was used as the standard antagonist. Stock solutions of both these standard drugs were prepared and then serially diluted in distilled water to give different concentrations.

EXAMPLE 10 Doses For In Vivo Gastric Activity Testing on M₁ Receptors

[0115] These activities were tested upon rats. The doses of methyl palmitate used were such as 1 milligram per kilogram of the body weight of rat injected subcutaneously (1 mg/kg s.c); 3 milligrams per kilogram of the body weight of rat (3 mg/kg s.c); 5 milligram per kilogram of the body weight of rat(5 mg/kg s.c).

[0116] For comparative purposes, the doses of atropine used for testing gastric acidity were such as 0.01 milligram per kilogram of the body weight of rat injected subcutaneously (0.01 mg/kg s.c); 0.05 milligram per kilogram of the body weight of rat injected subcutaneously (0.05 mg/kg s.c); 0.10 milligram per kilogram of the body weight of rat injected subcutaneously (0.10 mg/kg s.c)

EXAMPLE 11 Doses For In Vitro Testing on M₂ Receptors of Atrial Tissue

[0117] Four doses of methyl palmitate viz: 20× 10.super script .minus six moles per milli liter of bath concentration; 40× 10.super script .minus six moles per milli liter of bath concentration; 196× 10.super script .minus six moles per milli liter of bath concentration and 392× 10.super script .minus six moles per milli liter of bath concentration were prepared by diluting the stock solution with distilled water.

[0118] For comparative purposes the doses of atropine used were viz; 0.4× 10.super script .minus six moles per milli liter of bath concentration; 0.9× 10.super script .minus six moles per milli liter of bath concentration and 1.7× 10.super script .minus six moles per milliliter of bath concentration.

EXAMPLE 12 Doses of In Vitro Testing of M₃ Receptors of Ileum and Bladder

[0119] The three doses prepared and applied were 98× 10.super script .minus six moles per milli liter of bath concentration; 196× 10.super script .minus six moles per milli liter of bath concentration and 392× 10. super script .minus six moles per milliliter of bath concentration.

[0120] For comparative purposes, the three doses of atropine used were viz: 35× 10.super script .minus six moles per milli liter of bath concentration; 86× 10.super script .minus six moles per milliliter of bath concentration and 173× 10. super script .minus six moles per milli liter of bath concentration.

EXAMPLE 13 Administration of Methyl Palmitate for In Vivo Experiments

[0121] The in vivo experiments for gastric acidity testing were performed by pyloric ligation on rats. Albino rats of either sex weighing 190-250 grams were randomly divided into groups of 6, a group of 6 rats serving as control. All the rats were starved for 48 hours prior to the experiment. After the first 24 hrs., they were given access to 8% sucrose in 0.2% sodium chloride for 8 hours. Water was permitted ad libitum except during the 8 hours of sucrose treatment, & 2 hours. previous to pyloric ligation.

[0122] Basal gastric acidity was determined by pyloric ligation under ether anaesthesia followed by gastric lavage with normal saline. Except for the control group, all the rats received 3 doses (1, 3 & 5 mg/kg) of the said compound and standard antagonist atropine, (0.01, 0.05 & 0.1 mg/kg) subcutaneously 15 minutes prior to pyloric ligation. 3 hours after, the animals were killed, the stomach tied at the oesophageal junction and removed. The contents were collected by cutting along the greater curvature and the free acidity determined by titration against 0.01 normal NaOH using Topfers reagent as indicator.

EXAMPLE 14 In Vitro Experiments for Testing Antimuscarinic Activity of Methyl Palmitate

[0123] The in vitro experiments were performed on atria, ileum and bladder tissues of guinea pig.

[0124] Atria were removed and tied to an oxygen tube and the other end was fixed to a “Force transducer” (Model T-305) which is connected to a physiograph (Biodevices Physiograph). The atria beat spontaneously, and after equilibration (30 mins) resting tension was adjusted to the peak of the length tension curve followed by a re-equilibration period (30 mins). Cumulative concentration response curves to acetylcholine were obtained before and after addition of increasing concentrations of the compound (doses said in example 5). Responses were expressed as a percentage of the maximal inhibition of atrial rate induced by acetylcholine in absence of the antagonist (compound).

[0125] The longitudinal ileal muscle was suspended in an organ bath in aerated Tyrode solution. Antagonistic activity was determined from concentration response curves to acetylcholine in the absence or presence of increasing concentrations of the compound and of the muscarinic antagonist atropine. Doses of the compound were as given in example 5.

[0126] The longitudinal bladder detrusor strips were suspended under a resting tension (0.5 g) in aerated Tyrode physiological solution. Tension was measured with isometric force transducer (FT 305) and responses were recorded on a Biodevices Physiograph. Antimuscarinic activity was determined from concentration response curves to acetylcholine in the absence or presence of increasing concentrations of the said compound. Contractile responses were expressed as a percentage of the maximum contraction elicited by acetylcholine in the absence of the said compound. Doses of methyl palmitate, acetylcholine and atropine were as given in example 5.

EXAMPLE 15 Gastric Acidity

[0127] Like atropine the compound methyl palmitate inhibited basal gastric acidity dose dependently (Table 1) with all three doses (1, 3 & 5 mg/kg s.c.) At the lower dose inhibition was 50.72%, at 3 mg/kg it was 55.00%; while at the higher dose it was 91.50% respectively. Here, the compound was fifty times less potent than atropine as shown in the graphs (FIGS. 1 & 2).

EXAMPLE 16 Effect of Methyl Palmitate on M₂ Receptors of the Guinea Pig Atrium

[0128] The said compound did not produce any positive inotropic or chronotropic effect on its own in the concentrations studied i.e. 20×10⁻⁶ moles per ml of bath, 40×10⁻⁶ moles per ml of bath, 196×10⁻⁶ moles per ml of bath and 392×10⁻⁶ moles per ml of bath. The compound methyl palmitate is 118 fold less potent than atropine (FIGS. 3 and 4)

EXAMPLE 17

[0129] The compound methyl palmitate in concentrations of 98, 196 and 392×10⁻⁶ moles per ml of bath, antagonised contractions of smooth muscle of the ileum produced by the muscarinic agonist acetylcholine. Further, like atropine, this compound produced a shift to the right of the dose response curve to acetylcholine, with no change in the slope and maximum response, suggesting a competitive antagonism.(FIGS. 5 & 6). The compound is 2.2 times less potent than atropine.

EXAMPLE 18

[0130] Experiments on the strips of detrusor muscle of the bladder showed that the compound methyl palmitate in concentrations of 98×10⁻⁶ moles per ml of bath, 196×10⁻⁶ moles per ml of bath and 392×10⁻⁶ moles per ml of bath, antagonised the effect of acetylcholine in a dose—dependent and competitive manner (FIGS. 7 & 8). The said compound is 2.2 times less potent than atropine. TABLE 1 Effect of methyl palmitate and atropine on gastric acidity in rats. Dose Drug/ (mg/kg % Compound s.c.) inhibition ED_(50 (mg/kg)) Control Saline Atropine 0.01 09.00 0.05 42.00 0.055 0.10 91.15 Compound 1.0 50.72 02.74 (methyl 3.0 55.00 palmitate) 5.0 91.50 

1. A novel muscarine antagonist, comprising an effective amount of the compound methyl palmitate obtained from the mangrove plant Salvadora persica.
 2. A composition as claimed in claim 1, wherein the composition inhibits gastric acidity on M1 receptor in the muscles of the stomach of rat.
 3. A composition as claimed in claim 1, wherein the composition shows activity on M3 receptors of guinea pig ileal and bladder detrusor muscles.
 4. A method for the treatment of muscurine disorders, comprising the step of administering an effective amount of methyl palmitate obtained from the plant Salvadora persica.
 5. A method as claimed in claim 4 wherein the muscurine disorders are such as renal colitis, motion sickness, abdominal cramps and bronchial asthma.
 6. A method as claimed in claim 4 wherein the amount of methyl palmitate administered is 0.1 to 10 mg per kilogram of body weight.
 7. A process for producing methyl palmitate from a mangrove plant Salvadora persica, said process comprising (a) obtaining an extract from Salvadora persica, and (b) extracting and purifying the biologically active methyl palmitate from the extract.
 8. A process as claimed in claim 7, wherein the extract is prepared by: (i) air-drying the plant parts; (ii) immersing the plant parts in 90 percent aqueous methanol for one week at room temperature (28±2° C.); (iii) filtering the methanolic extract by conventional methods; and (iv) evaporating the methanolic extract at room temperature (28±2° C.) to obtain a crude extract.
 9. A process as claimed in claim 8, wherein the plant parts of Salvadora persica are selected from leaves, stems and flowers.
 10. A process as claimed in claim 8, wherein the extract is selected from chloroform extract, aqueous extract and hexane extract.
 11. A process as claimed in claim 8, wherein the extraction and purification of methyl palmitate is done by: a) Obtaining the extract of Salvadora persica; b) testing the extract using methods of pharmacology; c) fractionating the extract; d) testing the fractions using methods of pharmacology; e) isolating the pure methyl palmitate by any one of the conventionally known methods; f) testing the pure compound by using methods of pharmacology; and g) identifying the compound by any known method.
 12. A process as claimed in claim 8 wherein methyl palmitate is capable of distinguishing between muscarinic receptors of atrium and other parts of the body and shows heterogeneity of muscarinic receptors.
 13. A process as claimed in claim 8 wherein methyl palmitate inhibits gastric acidity and gastrointestinal disorders.
 14. A process as claimed in claim 8 wherein methyl palmitate inhibits gastric acidity on M1 receptor of stomach of rat.
 15. A process as claimed in claim 8 wherein methyl palmitate does not block M2 receptors and thereby does not have inhibitory effect on the contractions of atrial muscles of guinea pig in the dosage range used.
 16. A process as claimed in claim 8 wherein methyl palmitate shows activity on M3 receptors of guinea pig ileal and bladder detrusor muscles.
 17. A process as claimed in claim 8 wherein methyl palmitate produces a right shift of the dosage response curves of acetyl chlorine with the maximum response remaining the same.
 18. A process as claimed in claim 8 wherein methyl palmitate shows competitive antagonism which is reversible in nature.
 19. A process as claimed in claim 8 wherein methyl palmitate shows muscarinic activity with a milder potency than atropine.
 20. A method of treating gastric acidity and gastrointestinal disorders in mammals by administering methyl palmitate or an extract from a new mangrove plant source namely Salvadora persica.
 21. A method as claimed in claim 20 wherein the M1 receptor receive 0.1 to 10 mg of methyl palmitate per kilogram of body weight.
 22. A method as claimed in claim 20 wherein methyl palmitate is administered for every 15 minutes.
 23. A method as claimed in claim 20 wherein the M2 receptors receive 10×10⁻⁶ to 400×10⁻⁶ moles/ml of methyl palmitate.
 24. A method as claimed in claim 20 wherein methyl palmitate is administered for every 10 minutes.
 25. A method as claimed in claim 20 wherein the M3 receptors receive 50×10⁻⁶ to 400×10⁻⁶ moles/ml of methyl palmitate.
 26. A method as claimed in claim 20 wherein methyl palmitate is administered for every 60 seconds.
 27. A method as claimed in claim 20 wherein the M3 receptors are ileum and bladder.
 28. A method as claimed in claim 20 wherein the inhibition of gastric acidity is directly proportional to the increase in the dosage.
 29. Use of methyl palmitate or an extract obtained from new mangrove plant source namely Salvadora persica as muscarine antagonist in mammals.
 30. Use as claimed in claim 29 wherein methyl palmitate is capable of distinguishing between muscarinic receptors of atrium and other parts of the body and shows heterogeneity of muscarinic receptors.
 31. Use as claimed in claim 29 wherein methyl palmitate is capable of inhibiting gastric acidity and gastrointestinal disorders.
 32. Use as claimed in claim 29, wherein methyl palmitate is capable of inhibiting gastric acidity on M1 receptor of stomach of rat.
 33. Use as claimed in claim 29 wherein methyl palmitate does not block M2 receptors and thereby does not have inhibitory effect on the contractions of atrial muscles of guinea pig in the dosage range used.
 34. Use as claimed in claim 29 wherein methyl palmitate shows activity on M3 receptors of guinea pig ileal and bladder detrusor muscles.
 35. Use as claimed in claim 29 wherein methyl palmitate produces a right shift of the dosage response curves of acetyl chlorine with the maximum response remaining the same.
 36. Use as claimed in claim 29 wherein methyl palmitate shows competitive antagonism, which is reversible in nature.
 37. Use as claimed in claim 29 wherein methyl palmitate shows muscarinic activity with a milder potency than atropine.
 38. Use as claimed in claim 29 wherein the M1 receptor receives 0.1 to 10 mg of methyl palmitate per kilogram of body weight.
 39. Use as claimed in claim 29 wherein methyl palmitate is administered for every 15 minutes.
 40. Use as claimed in claim 29 wherein the M2 receptors receive 10×10⁻⁶ to 400×10⁻⁶ moles/ml of methyl palmitate.
 41. Use as claimed in claim 29 wherein methyl palmitate is administered for every 10 minutes.
 42. Use as claimed in claim 29 wherein the M3 receptors receive 50×10⁻⁶ to 400×10⁻⁶ moles/ml of methyl palmitate.
 43. Use as claimed in claim 29 wherein methyl palmitate is administered for every 60 seconds. 